Altimmune (ALT) vs Prelude Therapeutics (PRLD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed Altimmune (ALT) over the past year, gaining 93.4% versus a loss of 72.3%. Over five years, PRLD leads with a -76.9% price change compared with -87.2% for ALT. Altimmune is the larger company by market cap ($258.8 million vs $258.6 million), about 1.0 times the size.
Prelude Therapeutics converts more of its revenue into profit, with a net margin of -819.6% versus -214861.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | PRLD |
|---|---|---|
| Share price | $1.33 | $3.23 |
| Market cap | $258.80M | $258.63M |
| 1-day change | -5.67% | -0.77% |
| YTD return | -63.16% | +11.38% |
| 1-year return | -72.35% | +93.41% |
| 5-year return | -87.24% | -76.93% |
| EPS (TTM) | $-0.71 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $41.00K | $12.14M |
| Revenue growth (YoY) | +105.00% | +73.43% |
| Net income (latest FY) | $-88.09M | $-99.50M |
| Operating margin | -230460.98% | -861.33% |
| Net margin | -214860.98% | -819.59% |
| 52-week high | $6.44 | $6.83 |
| 52-week low | $1.32 | $1.30 |
| Distance from 52-week high | -79.35% | -52.71% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1127.82% | +172.45% |
| Average volume | 3.91M | 432.74K |
| Shares outstanding | 194.59M | 65.34M |
| Employees | 57 | 79 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed ALT by 165.8 percentage points over the past year.
- Prelude Therapeutics is more profitable, keeping -819.6 cents of every revenue dollar as net income versus -214861.0 cents for Altimmune.
- Altimmune grew revenue faster in its latest fiscal year (+105.00% vs +73.43%).
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
ALT vs PRLD FAQ
Which is bigger, Altimmune or Prelude Therapeutics?
Altimmune (ALT) is larger, with a market capitalization of $258.80M compared with $258.63M for Prelude Therapeutics (PRLD).
Which stock has performed better over the past year, ALT or PRLD?
PRLD returned +93.41% over the past 12 months, compared with -72.35% for ALT (price return, excluding dividends). Past performance does not predict future results.
Are Altimmune and Prelude Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.